PGS

Pre-implantation Genetic Screening

Genesis-24, also known as Pre-Implantation Genetic Screening (PGS), is an IVF procedure designed to examine your embryos for chromosomal abnormalities. An embryo biopsy is taken either at day 3 or day 5 and Genesis-24 is used to examine all 24 chromosomes—the 22 non-sex chromosomes plus the two sex chromosomes (X & Y) in time for your embryo transfer. Chromosomal abnormalities can result in aneuploidy (embryos having wrong number of chromosomes – e.g. extra copy of chromosome 21 also known as Downs Syndrome), translocations (chromosomes incorrectly rearranged), or other chromosome alterations that may be clinically significant. Genesis-24 aims at improving pregnancy and live birth rates by screening your embryos for chromosomal abnormalities and only implanting chromosomally normal embryos.

Genesis-24: The Technology & The Process

Genesis-24 screening can potentially benefit couples who present with the majority of IVF indications. Particularly advanced maternal age couples and families who have had recurrent pregnancy losses both naturally and through IVF.

A declining live birth rate is an increasing problem for families who choose to have children later in life and is strongly associated with late maternal age embryos showing greater levels of chromosomal abnormalities. Without Genesis-24, embryos are chosen based only on their visual quality and morphology, which cannot distinguish chromosome normal from abnormal embryos. In IVF cycles that incorporate Genesis-24, embryos are assessed both by morphology and their chromosome content. Using Genesis-24 embryos with the normal number of chromosomes are selected and are more likely to result in a pregnancy that is carried to full term. Our rapid, accurate and confidential testing allows our patients to have fresh embryo transfers. Such testing gives our parents-to-be peace of mind.

Female Chromosome

Male chromosome

Genesis-24 screening utilizes the most sophisticated and scientifically validated technology for determining the chromosome compliment in a single cell. Comparative Genomic Hybridization (CGH) is a micro-array technology that compares the DNA in the embryo sample to a known normal control using thousands of genetic markers throughout the human genome. Our scientists obtain and interpret a computer generated map for each embryo sample. Genesis Genetics then provides a detailed genetic report to your IVF physician, indicating which embryos are chromosomally normal, in time for your embryo transfer.

This technology is the global standard. It is the only technology accepted by the European Society of Human Reproduction and Embryology (ESHRE).

To learn more, email our team at ggeulab1@genesisgenetics.org

About Us

Genesis Genetics is the pioneer of preimplantation testing of embryos for inherited genetic abnormalities, and was founded by world renowned scientists largely responsible for discovering preimplantation genetic diagnosis (PGD) as a clinical practice and performed the first successful cases in the world.

 

Contact Genesis Genetics

London Biosciences Innovation Centre
London NW1 0NH
Phone: +44 (0)20 7691 2084
Email: ggeulab1@genesisgenetics.org
Join Us on Facebook »
website security